OmniCyte Founder, Peter Leonardi, provides insight into the emerging field of immunotherapy. Immunotherapy is the process that uses the body’s natural defense system to cure cancer. The most popular area is in […]
Bristol-Myers Squibb Company (BMS) announced Tuesday that it had signed an agreement to acquire biopharmaceutical company ZymoGenetics for approximately $885 million, or $9.75 per share in cash.
Approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year.
Inovio is developing a universal flu vaccine engineered to prevent several strains of influenza at once.
Inovio Biomedical (AMEX: INO) is developing a robust pre-clinical and early clinical stage pipeline of innovative DNA-based vaccines and therapeutics that target cancer, influenza, and other infectious diseases (e.g. HIV) based on its SynCon DNA vaccine construct and electroporation DNA delivery technology platforms.
Solid tumors represent 85 percent of all cancers, creating a huge clinical need for localized, site-specific cancer treatment. Inovio Medical Corporation of San Diego is developing DNA-based vaccines that harness the body’s immune system to prevent and treat chronic diseases such as cancer and HIV.
